Market Overview

UPDATE: ISI Group Cuts PT to $39 on Charles River Laboratories Following Negative Guidance

Share:
Related CRL
Positives In Charles River Labs 'Largely Reflected In Industry-High Valuation'
Mid-Morning Market Update: Markets Open Higher; Time Warner Posts Mixed Q4 Results

ISI Group reiterated its Underweight rating on Charles River Laboratories (NYSE: CRL) and lowered its price target from $40.50 to $39.

ISI Group commented, "As a result of today's 2013 guidance announcement, we are lowering CRL's FY13 EPS from $3.10 to $3.00 and FY14 EPS from $3.45 to $3.25. These EPS changes stem from lower operating margin expectations due to the aforementioned investment headwinds. Despite the improved revenue outlook, limited visibility across the business (ex strategic deals) and a challenged OM outlook will limit P/E expansion, and in turn, cap shares in the upper $30s."

Charles River Laboratories closed at $36.55 on Tuesday.

Latest Ratings for CRL

DateFirmActionFromTo
Aug 2016JefferiesMaintainsBuy
Aug 2016CitigroupMaintainsNeutral
Jun 2016Credit SuisseInitiates Coverage onNeutral

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!